| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1517/13543780903373343 |
| P698 | PubMed publication ID | 19938898 |
| P50 | author | Giuseppe Giaccone | Q37829946 |
| P2093 | author name string | Corey A Carter | |
| Ronan J Kelly | |||
| P2860 | cites work | KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib | Q21563446 |
| Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941 | Q24321567 | ||
| Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3 | Q24633878 | ||
| MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib | Q24646295 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain | Q24794765 | ||
| Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 | ||
| EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy | Q27824812 | ||
| EGFR mutation and resistance of non-small-cell lung cancer to gefitinib | Q27824829 | ||
| Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib | Q27851394 | ||
| Lapatinib plus capecitabine for HER2-positive advanced breast cancer | Q27851403 | ||
| MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling | Q27851406 | ||
| Met, metastasis, motility and more | Q28235183 | ||
| Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors | Q28272463 | ||
| Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways | Q28274882 | ||
| Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function | Q28678683 | ||
| Erlotinib in previously treated non-small-cell lung cancer | Q29547546 | ||
| Epidermal growth factor receptor mutations in lung cancer | Q29615474 | ||
| Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group | Q29619344 | ||
| Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) | Q29620605 | ||
| Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial | Q33361488 | ||
| ErbB receptors and EGF-like ligands: cell lineage determination and oncogenesis through combinatorial signaling | Q33959306 | ||
| Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial | Q34271566 | ||
| Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck | Q34287207 | ||
| Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase | Q34323951 | ||
| Biology of HER2 and its importance in breast cancer | Q34428745 | ||
| TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. | Q34436986 | ||
| Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck | Q34533587 | ||
| Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. | Q34533636 | ||
| Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. | Q34545921 | ||
| Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. | Q34545926 | ||
| A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma | Q34553224 | ||
| Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations | Q34568507 | ||
| A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer | Q34650878 | ||
| ErbB/HER ligands in human breast cancer, and relationships with their receptors, the bio-pathological features and prognosis | Q34706896 | ||
| Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase | Q35160181 | ||
| Epidermal growth factor receptor family tyrosine kinases as signal integrators and therapeutic targets | Q35186456 | ||
| Epidermal growth factor receptor and bladder cancer: a review | Q35268041 | ||
| Targeting the HER-kinase axis in cancer | Q35723785 | ||
| Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer | Q35914677 | ||
| Activating mutations for the met tyrosine kinase receptor in human cancer | Q36595980 | ||
| Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). | Q36701598 | ||
| HKI-272 in non small cell lung cancer. | Q36899870 | ||
| A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer | Q37087832 | ||
| HER-2 positive breast cancer: what else beyond trastuzumab-based therapy? | Q37184721 | ||
| Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors | Q37316206 | ||
| Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. | Q38425937 | ||
| Prognostic impact of HER-2/neu expression on squamous head and neck carcinomas. | Q38433814 | ||
| Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer | Q38441379 | ||
| HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas | Q38474138 | ||
| Somatic mutations of the ERBB4 kinase domain in human cancers | Q38512879 | ||
| Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines | Q40106465 | ||
| Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer | Q40178699 | ||
| Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer | Q40489484 | ||
| Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. | Q40502745 | ||
| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer | Q40544950 | ||
| Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells | Q40670668 | ||
| Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis | Q41460315 | ||
| Specificity within the EGF family/ErbB receptor family signaling network | Q41721612 | ||
| Endometrial K-ras mutations in postmenopausal breast cancer patients treated with adjuvant tamoxifen or toremifene | Q45183881 | ||
| Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies | Q45246419 | ||
| Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun | Q45309210 | ||
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. | Q46027726 | ||
| Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. | Q46232500 | ||
| A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer | Q46482960 | ||
| First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations | Q46610982 | ||
| Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib | Q46618741 | ||
| A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. | Q46625058 | ||
| Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study | Q46712990 | ||
| Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib | Q46735182 | ||
| Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy | Q46796554 | ||
| Differential expression of NDF/neuregulin receptors ErbB-3 and ErbB-4 and involvement in inhibition of neuronal differentiation. | Q48570258 | ||
| EGFR exon 20 insertion mutation in Japanese lung cancer. | Q50940170 | ||
| Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer. | Q52590998 | ||
| A Phase I Study of Cetuximab/Paclitaxel in Patients with Advanced-Stage Breast Cancer | Q57578464 | ||
| Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer | Q57918738 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1829-1842 | |
| P577 | publication date | 2009-12-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Small-molecule inhibitors of the human epidermal receptor family | |
| P478 | volume | 18 |
| Q28543168 | 3-Dimensional culture systems for anti-cancer compound profiling and high-throughput screening reveal increases in EGFR inhibitor-mediated cytotoxicity compared to monolayer culture systems |
| Q37890206 | Changing pathology with changing drugs: skin cancer. |
| Q37967108 | Cutaneous lymphomas: molecular pathways leading to new drugs |
| Q33635861 | Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors |
| Q35098322 | Emerging drugs to treat squamous cell carcinomas of the head and neck |
| Q37146309 | GUCY2C ligand replacement to prevent colorectal cancer. |
| Q35654201 | Increased activation of the PI3K/AKT pathway compromises decidualization of stromal cells from endometriosis. |
| Q34581860 | Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo |
| Q35528877 | Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16 |
| Q34203794 | Loss of Inositol Polyphosphate 5-Phosphatase Is an Early Event in Development of Cutaneous Squamous Cell Carcinoma |
| Q37000422 | Molecular characterization of head and neck cancer: how close to personalized targeted therapy? |
| Q35875753 | Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer |
| Q34683348 | Targeted Inhibition of Kinases in Cancer Therapy |
| Q33722761 | Translating colorectal cancer prevention through the guanylyl cyclase C signaling axis |
Search more.